Commissioning guide:
Gastro-oesophageal reflux disease (GORD)

Sponsoring Organisation: Association of Upper Gastrointestinal Surgeons
Date of evidence search: March 2013
Date of publication: September 2013
Date of Review: September 2016

NICE has accredited the process used by Surgical Speciality Associations and Royal College of Surgeons to produce its Commissioning guidance. Accreditation is valid for 5 years from September 2012. More information on accreditation can be viewed at www.nice.org.uk/accreditation
CONTENTS

Glossary ................................................................................................................................. 2
Introduction ............................................................................................................................. 2

1 High Value Care Pathway for GORD ................................................................................. 2
   1.1 Primary Care ................................................................................................................ 2
   1.2 Secondary Care .......................................................................................................... 4

2 Procedures explorer for GORD ......................................................................................... 5

3 Quality dashboard for GORD ............................................................................................ 6

4 Levers for implementation ............................................................................................... 7
   4.1 Audit and peer review measures ................................................................................. 7
   4.2 Quality Specification/CQUIN .................................................................................... 7

5 Directory ............................................................................................................................. 8
   5.1 Patient Information for GORD .................................................................................. 8
   5.2 Clinician information for GORD .............................................................................. 8

6 Benefits and risks of implementing this guide ............................................................... 9

7 Further information ........................................................................................................... 9
   7.1 Research recommendations ....................................................................................... 9
   7.3 Evidence base ............................................................................................................. 9
   7.4 Guide development group for GORD ....................................................................... 10
   7.5 Funding statement ..................................................................................................... 11
   7.6 Conflict of interest statement .................................................................................. 11
Introduction

This guide focuses on the treatment of gastro-oesophageal reflux symptoms, such as heartburn, regurgitation and swallow discomforts. It should be understood that for most this is a chronic, lifelong condition, requiring a balance of lifestyle measures, medical treatments and occasionally referral for further interventions.

e-mail: manager@augis.org

www.augis.org

1 High Value Care Pathway for GORD

1.1 Primary Care

History

▪ Review of all current medication and over-the-counter herbal preparations, specifically NSAIDs/ corticosteroids/ bisphosphonates/ nitrates/ theophylline.

▪ Identify psychological–social stressors.

▪ Assess severity of symptoms – Use GerdQ (see directory [patient information] below).

▪ Physical examination to rule out upper abdominal mass.

Investigation

▪ Full blood count/urea and electrolytes/liver function test/coeliac screen (if iron deficiency anaemia) may assist decision on specialist assessment.
Refer urgently in accordance with local guidelines to a team specialising in the diagnosis of upper GI cancer if any of the following detected:

- Dysphagia
- Progressive unintentional weight loss
- Persistent vomiting
- Dyspepsia or reflux and Iron deficiency anaemia, or chronic gastrointestinal bleed
- Epigastric mass/suspicious barium meal
- >55 years with unexplained and persistent (>4–6 week) recent-onset reflux
- Worsening reflux with known Barrett’s oesophagus/ atrophic gastritis/ intestinal metaplasia/ dysplasia or previous peptic ulcer surgery /family history of upper GI cancer in more than two first-degree relatives

Offer all patients advice regarding:

- Lifestyle and healthy eating. Suggest that the patient decrease the fat content in their diet; make the patient aware of potential food triggers including chocolate/coffee/alcohol/onion/garlic/spicy foods
- Weight reduction
- Smoking cessation
- Avoiding recumbency for three hours after meals
- Raising head of bed by 20 cm, or using multiple pillows
- Management of psychological–social stressors if present

Evidence to support this advice is weak but adjustments can help patients cope with reflux so should be considered and tried.

Medical treatment

- Alginateantacid combination/H2RA treatments useful for mild heartburn.
- A trial of a PPI for one to two months for more persistent symptoms. Many patients require long term therapy necessitating at least annual review. Aim to use lowest effective dose.
- If the patient responds poorly to PPI consider doubling the dose. Reassessment at two to three months +/- Upper GI Endoscopy if symptoms continue.
- If additional medication needed to control symptoms consider prokinetics such as domperidone.
- If PPI is not well tolerated or effective then patients may respond to H2RA.
Refer to secondary care provider if:

- The patient’s quality of life remains significantly impaired and there are persistent symptoms despite medical treatment and lifestyle modification, or if the patient expresses a preference to consider surgery rather than continue long term medical treatment. Perform a GerdQ Questionnaire to identify the degree of symptom burden before onward referral as this can be useful in postoperative follow-up.

1.2 Secondary Care

Secondary care will provide a re-assessment of the need for further intervention and a balance of the potential risks and outcomes.

Indications for surgical procedures include:

- Volume reflux, especially affecting sleep, or during physical activities that involve stooping.
- Breakthrough symptoms of heartburn despite optimal medical therapy.
- Intolerance of proton pump inhibitors.
- Patient preference to avoid lifelong medication.
- Post prandial chest pain, or dysphagia from incarcerated para-oesophageal hernia.
- Atypical symptoms such as aspiration, cough or hoarse voice if confirmed on pH testing.

Investigation

- Upper GI Endoscopy to assess the degree of oesophageal injury, diagnose the presence or absence of Barrett’s oesophagus and biopsy to exclude Eosinophilic oesophagitis or oesophageal malignancy.
- Oesophageal manometry and 24-hour pH monitoring studies to prove the presence of pathological reflux and to exclude the presence of underlying oesophageal motility disorders.

What does surgery involve?

Laparoscopic anti-reflux surgery can be performed as a day case or with a short inpatient admission. There are a number of different surgical procedures described (eg Nissen, Toupet and Watson fundoplications), which are all variations of the degree and shape of folding the stomach around the lower oesophagus. The components of anti-reflux surgery involve:

1. Repairing the hiatus (the opening in the diaphragm through which the oesophagus passes) which will fix a hiatus hernia.
2. Fundoplication which creates a barrier to the reflux of gastric contents into the oesophagus by wrapping the upper part of the stomach (fundus) around the oesophagus, creating a sling. There is debate around the ‘optimal’ fundoplication, but the approach depends on the training and personal experience of the operating surgeon. It would not be appropriate to recommend any particular type of fundoplication over another.
A different approach may be necessary when there is a large (possibly obstructing) para-oesophageal hernia, when a large amount of stomach has prolapsed into the chest. This tends to occur in the elderly and it is sometimes only necessary to repair the diaphragmatic defect and fix the stomach in the abdomen (gastropexy) without performing a fundoplication.

The most important determinant of a good outcome in a population after anti-reflux surgery is appropriate selection of patients for surgery. There are some situations where an adverse outcome is more likely and they include:

- Failure of acid suppression to make any difference to symptom control. Classical and volume reflux symptoms should be partially controlled or, at least, helped by acid-suppression therapy.
- Normal preoperative 24-hour pH tracing.
- Co-existent oesophageal motility disorder.
- Gastroparesis or significant symptoms suggestive of irritable bowel syndrome.
- Atypical reflux symptoms – this group has a lower success rate from surgery than patients with classical or volume reflux.

2 Procedures explorer for GORD

1. Nissen 360 degree fundoplication + repair hiatus
2. Watson partial anterior fundoplication + repair hiatus
3. Toupet partial posterior fundoplication repair hiatus
4. Gastropexy + repair hiatus hernia

Procedures that are under research regulation or restricted to long term registry follow-up (these are not recommended for commissioning but may form part of the range of procedures offered at specialist centres performing suitable registered research projects):

1. Stretta: endoscopic microwave ablation
2. Esophyx: endoscopic plication
3. Linx: magnetic bead bracelet around oesophagus
4. Endostim: electrical stimulation of the lower oesophageal sphincter

Users can access further procedure information based on the data available in the quality dashboard to see how individual providers are performing against the indicators. This will enable CCGs to start a conversation with providers who appear to be 'outliers' from the indicators of quality that have been selected.

The Procedures Explorer Tool is available via the Royal College of Surgeons website.
3 Quality dashboard for GORD

Laparoscopic anti-reflux surgery has a low mortality (<0.3%) with most deaths ascribed to postoperative cardiac events. Complications specific to laparoscopic anti-reflux surgery can be divided into immediate or delayed, with the former being much rarer, but tending to require operative intervention.

Immediate complications include:

- bleeding;
- perforation of oesophagus/proximal stomach;
- re-herniation of the stomach into the chest; and
- slippage of the wrap.

Delayed complications include:

- dysphagia (difficulty in swallowing), which is very common in the first few weeks and usually settles spontaneously;
- gas bloat – the sensation of ‘trapped wind’ after eating due to the inability to ‘burp’ after surgery; and
- diarrhoea – relatively rare and the exact mechanism is unclear.

The quality dashboard provides an overview of activity commissioned by CCGs from the relevant pathways, and indicators of the quality of care provided by surgical units.

The quality dashboard is available via the Royal College of Surgeons website.
4 Levers for implementation

4.1 Audit and peer review measures
The following measures and standards are those expected at primary and secondary care. Evidence should be made available to commissioners if requested.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary care</td>
<td><strong>Assessment</strong> Use of the GERDQ questionnaire before referral</td>
</tr>
<tr>
<td></td>
<td><strong>Referral</strong> Appropriate lifestyle and medical therapy and review before referral</td>
</tr>
<tr>
<td></td>
<td><strong>Assessment</strong> Ensure adequate balance of potential risks and benefits of endoscopy, manometry and pH tests before decision for intervention</td>
</tr>
<tr>
<td></td>
<td><strong>Intervention</strong> Offer procedures with NICE recommendation. Do not offer untested procedures outside registered research trial</td>
</tr>
<tr>
<td>Secondary care</td>
<td><strong>Assessment</strong> Ensure adequate balance of potential risks and benefits of endoscopy, manometry and pH tests before decision for intervention</td>
</tr>
<tr>
<td></td>
<td><strong>Intervention</strong> Offer procedures with NICE recommendation. Do not offer untested procedures outside registered research trial</td>
</tr>
</tbody>
</table>

4.2 Quality Specification/CQUIN

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
<th>Data specification (if required)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Length of stay</strong></td>
<td>Provider demonstrates a median of two days</td>
<td>Data available from HES</td>
</tr>
<tr>
<td><strong>Day case rates</strong></td>
<td>Provider demonstrates a day case rate for anti-reflux procedure</td>
<td>Data available from HES</td>
</tr>
</tbody>
</table>
5 Directory

5.1 Patient Information for GORD

<table>
<thead>
<tr>
<th>Name</th>
<th>Publisher</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acid reflux and oesophagitis</td>
<td>Patient.co.uk</td>
<td><a href="http://www.patient.co.uk/health/acid-reflux-and-oesophagitis">http://www.patient.co.uk/health/acid-reflux-and-oesophagitis</a></td>
</tr>
<tr>
<td>Fight Oesophageal reflux together</td>
<td>FORT</td>
<td><a href="http://www.fortcharity.org.uk">http://www.fortcharity.org.uk</a></td>
</tr>
<tr>
<td>Heartburn and cancer awareness and support</td>
<td>HCAS</td>
<td><a href="http://www.h-cas.org">http://www.h-cas.org</a></td>
</tr>
<tr>
<td>GERD-Q questionnaire</td>
<td></td>
<td><a href="http://www.soapnote.org/digestive-system/gerdq/">http://www.soapnote.org/digestive-system/gerdq/</a></td>
</tr>
</tbody>
</table>

5.2 Clinician information for GORD

<table>
<thead>
<tr>
<th>Name</th>
<th>Publisher</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>GORD guidance (in development)</td>
<td>NICE</td>
<td><a href="http://guidance.nice.org.uk/CG/Wave0/609">http://guidance.nice.org.uk/CG/Wave0/609</a></td>
</tr>
</tbody>
</table>
6 Benefits and risks of implementing this guide

<table>
<thead>
<tr>
<th>Consideration</th>
<th>Benefit</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient outcome</td>
<td>Ensure access to effective conservative, medical and surgical therapy</td>
<td>Unrecognised deterioration on conservative therapy</td>
</tr>
<tr>
<td>Patient safety</td>
<td>Reduce chance of missing oesophageal malignancy</td>
<td>Unrecognised deterioration on conservative therapy</td>
</tr>
<tr>
<td></td>
<td>Reduce re-operations for reflux disease</td>
<td></td>
</tr>
<tr>
<td>Patient experience</td>
<td>Improve access to patient information, support groups</td>
<td>Inappropriate or excess self-medication</td>
</tr>
<tr>
<td>Equity of access</td>
<td>Improve access to effective procedures</td>
<td>Unnecessary and ineffective surgery</td>
</tr>
<tr>
<td>Resource impact</td>
<td>Reduce unnecessary referral and intervention</td>
<td></td>
</tr>
</tbody>
</table>

7 Further information

7.1 Research recommendations

- Use of GERD-Q score to guide referral and management

7.3 Evidence base

5. Grant AM, Boachie C, Cotton SC, Faria R, Bojke L, Epstein D et al. Clinical and economic evaluation of...


7.4 Guide development group for GORD

A commissioning guide development group was established to review and advise on the content of the commissioning guide. This group met once, with additional interaction taking place via email and teleconference.

<table>
<thead>
<tr>
<th>Name</th>
<th>Job title/role</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Professor Stephen Attwood</strong></td>
<td>Chair and Consultant General Surgeon</td>
<td>AUGIS</td>
</tr>
<tr>
<td>Mr Ashraf Rasheed</td>
<td>Consultant General Surgeon</td>
<td>AUGIS</td>
</tr>
<tr>
<td>Mr Colin McKay</td>
<td>Consultant General Surgeon</td>
<td>AUGIS</td>
</tr>
<tr>
<td>Mr Ian Beckingham</td>
<td>Consultant General Surgeon</td>
<td>AUGIS</td>
</tr>
<tr>
<td>Dr John Painter</td>
<td>Consultant Gastroenterologist</td>
<td>City Hospitals Sunderland, NHS Foundation Trust</td>
</tr>
<tr>
<td>Mr Kenneth Appel</td>
<td>Patient</td>
<td>LINk/Healthwatch Representative, West Hertfordshire Hospitals Trust</td>
</tr>
<tr>
<td>Ms Marlene Moura</td>
<td>Patient</td>
<td>Essex and SouthendLINk/Healthwatch</td>
</tr>
</tbody>
</table>
Commissioning guide 2013

GORD

<table>
<thead>
<tr>
<th>Dr Richard Day</th>
<th>Consultant in Geriatric Medicine, Poole Hospital</th>
<th>Southampton City CCG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Sarah Hillson</td>
<td>GP</td>
<td>Brook Green Medical Centre, Hammersmith, London</td>
</tr>
</tbody>
</table>

7.5  Funding statement

The development of this commissioning guidance has been funded by the following sources:

- DH Right Care funded the costs of the guide development group, literature searches and contributed towards administrative costs.

- The Royal College of Surgeons of England and the Association of Upper Gastrointestinal Surgeons (AUGIS) of Great Britain and Ireland provided staff to support the guideline development.

7.6  Conflict of interest statement

Individuals involved in the development and formal peer review of commissioning guides are asked to complete a conflict of interest declaration. It is noted that declaring a conflict of interest does not imply that the individual has been influenced by his or her secondary interest. It is intended to make interests (financial or otherwise) more transparent and to allow others to have knowledge of the interest.

**There were no interests declared by the group.**